This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04698915
Recruitment Status : Terminated (Futility Analysis)
First Posted : January 7, 2021
Last Update Posted : December 13, 2023
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : November 30, 2023
Actual Study Completion Date : November 30, 2023
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 March 1, 2024
March 26, 2024 Submission with QC Comments
2 March 27, 2024